Payment overview · 2025
General Payments
$94,916.22
246 reported records · 26 companies
Healthcare provider profile · identity verified
John Caleb Browning, MD
Allopathic & Osteopathic Physicians|Dermatology · SAN ANTONIO, TX · NPI 1124181615
Verified facts
What the public records show
CMS Open Payments records show John Caleb Browning, MD received $94,916.22 in general payments during 2025 across 246 reported records.
Galderma Laboratories, L.P. accounted for 56.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Hyftor, Nemluvio, Tremfya.
Galderma Laboratories, L.P. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEMLUVIO as an associated drug or biological on 72893 records involving 14128 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nemluvio by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 23706 records involving 7279 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Stelara by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Tremfya by this doctor in 2024.
NOBELPHARMA AMERICA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HYFTOR as an associated drug or biological on 208 records involving 169 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Hyftor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $53,939.84 | 56.8% | 51 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $17,501.67 | 18.4% | 27 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $9,698.60 | 10.2% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $5,054.10 | 5.3% | 16 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $4,571.58 | 4.8% | 12 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $894.20 | 0.9% | 12 | 2025 |
| NOBELPHARMA AMERICA, LLC | Unresolved — no canonical attribution shown | $700.00 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $518.77 | 0.6% | 24 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $346.07 | 0.4% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $288.16 | 0.3% | 10 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $211.21 | 0.2% | 6 | 2025 |
| Arcutis Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $205.44 | 0.2% | 12 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $167.43 | 0.2% | 12 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $129.89 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $124.29 | 0.1% | 6 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $117.33 | 0.1% | 8 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $98.90 | 0.1% | 5 | 2025 |
| Verrica Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.47 | 0.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.44 | 0.1% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $45.78 | 0.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $43.13 | 0.1% | 2 | 2025 |
| Biofrontera Inc. | Unresolved — no canonical attribution shown | $37.91 | 0.0% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $28.46 | 0.0% | 1 | 2025 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.08 | 0.0% | 2 | 2025 |
| Botanix SB Inc | Unresolved — no canonical attribution shown | $22.10 | 0.0% | 1 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $21.37 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $81,431.00 | 28 |
| Consulting Fee | $6,005.00 | 2 |
| Food and Beverage | $5,028.28 | 208 |
| Honoraria | $1,440.00 | 2 |
| Travel and Lodging | $969.87 | 3 |
| Education | $42.07 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $53,924.02 | 50 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $17,501.67 | 27 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $5,054.10 | 16 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $4,703.14 | 26 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $784.11 | 4 | 2025 |
Source payment records
|
|||||
| HYFTOR Normalized: hyftor |
Drug | NOBELPHARMA AMERICA, LLC | $700.00 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $346.07 | 10 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $321.03 | 16 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $211.21 | 6 | 2025 |
Source payment records
|
|||||
| LITFULO Normalized: litfulo |
Drug | PFIZER INC. | $209.10 | 14 | 2025 |
Source payment records
|
|||||
| Zoryve Normalized: zoryve |
Drug | Arcutis Biotherapeutics, Inc. | $205.44 | 12 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $202.22 | 9 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $202.22 | 9 | 2025 |
Source payment records
|
|||||
| FILSUVEZ Normalized: filsuvez |
Drug | Chiesi USA, Inc. | $129.89 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $129.11 | 5 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $117.33 | 8 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $117.33 | 8 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $98.90 | 5 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $82.74 | 4 | 2025 |
Source payment records
|
|||||
| ILUMYA Normalized: ilumya |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $82.70 | 4 | 2025 |
Source payment records
|
|||||
| YCANTH Normalized: ycanth |
Drug | Verrica Pharmaceuticals Inc. | $63.47 | 2 | 2025 |
Source payment records
|
|||||
| SPEVIGO Normalized: spevigo |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $58.44 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $45.78 | 2 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $43.13 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $38.67 | 2 | 2025 |
Source payment records
|
|||||
| Leqselvi Normalized: leqselvi |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $34.46 | 3 | 2025 |
Source payment records
|
|||||
| BLU-U Normalized: blu u |
Medical Supply | SUN PHARMACEUTICAL INDUSTRIES INC. | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| Winlevi Normalized: winlevi |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $31.90 | 5 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| JUBLIA Normalized: jublia |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $28.08 | 2 | 2025 |
Source payment records
|
|||||
| AMELUZ Normalized: ameluz |
Drug | Biofrontera Inc. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| BF-RHODOLED Normalized: bf rhodoled |
Device | Biofrontera Inc. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| RHODOLED XL Normalized: rhodoled xl |
Device | Biofrontera Inc. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| SOFDRA Normalized: sofdra |
Drug | Botanix SB Inc | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| ANZUPGO Normalized: anzupgo |
Drug | LEO Pharma Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $17.04 | 2 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| AKLIEF Normalized: aklief |
Drug | Galderma Laboratories, L.P. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $13.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| HYFTOR hyftor |
2025 | Hyftor | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEMLUVIO nemluvio |
2025 | Nemluvio | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Galderma Laboratories, L.P. Exact reporting entity; no affiliate inference |
2025 | NEMLUVIO open payments reported associated product |
CMS Open Payments — General Payments 72893 supporting records · 14128 recipient NPIs · example record 1234610934 |
Nemluvio · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 23706 supporting records · 7279 recipient NPIs · example record 1174257377 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| NOBELPHARMA AMERICA, LLC Exact reporting entity; no affiliate inference |
2025 | HYFTOR open payments reported associated product |
CMS Open Payments — General Payments 208 supporting records · 169 recipient NPIs · example record 1254656001 |
Hyftor · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ketoconazole | Ketoconazole | 418 | 148 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 364 | 181 |
| Clobetasol Propionate | Clobetasol Propionate | 295 | 143 |
| Doxycycline Hyclate | Doxycycline Hyclate | 156 | 75 |
| Ammonium Lactate | Ammonium Lactate | 155 | 73 |
| Minoxidil | Minoxidil | 126 | 32 |
| Mometasone Furoate | Mometasone Furoate | 102 | 41 |
| Mupirocin | Mupirocin | 93 | 66 |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 75 | 19 |
| Dupixent Pen | Dupilumab | 68 | suppressed |
| Fluocinonide | Fluocinonide | 66 | 28 |
| Hydrocortisone | Hydrocortisone | 53 | 29 |
| Clindamycin Phosphate | Clindamycin Phosphate | 47 | 13 |
| Dupixent Syringe | Dupilumab | 46 | suppressed |
| Latanoprost | Latanoprost | 45 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 13 |
| Metronidazole | Metronidazole | 39 | 20 |
| Fluorouracil | Fluorouracil | 38 | 18 |
| Humira(Cf) Pen | Adalimumab | 37 | suppressed |
| Finasteride | Finasteride | 32 | 11 |
| Tacrolimus | Tacrolimus | 32 | 15 |
| Imiquimod | Imiquimod | 30 | 19 |
| Desonide | Desonide | 29 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 15 |
| Betamethasone Valerate | Betamethasone Valerate | 26 | 13 |
| Tretinoin | Tretinoin | 25 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 24 | 14 |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 21 | suppressed |
| Hyftor | Sirolimus | 20 | suppressed |
| Otezla | Apremilast | 19 | suppressed |
| Tremfya | Guselkumab | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Permethrin | Permethrin | 15 | suppressed |
| Stelara | Ustekinumab | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Nemluvio | Nemolizumab-Ilto | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Azelaic Acid | Azelaic Acid | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Erivedge | Vismodegib | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94,916.22 · 246 records | Galderma Laboratories, L.P. | AKLIEF, AMELUZ, ANZUPGO, BF-RHODOLED, BLU-U, BOTOX, Bimzelx, CIBINQO, COSENTYX, DAXXIFY, DUPIXENT, EBGLYSS, FILSUVEZ, HYFTOR, ILUMYA, JUBLIA, Kerecis GraftGuide, Kerecis SurgiClose, LIBTAYO, LITFULO, Leqselvi, NEMLUVIO, NEXPLANON, Natroba, OPZELURA, Odomzo, RHODOLED XL, RINVOQ, Rhapsido, SKYRIZI, SOFDRA, SPEVIGO, Sotyktu, Spinosad, TALTZ, TREMFYA, VTAMA, VYJUVEK, Winlevi, YCANTH, Zoryve | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Hyftor play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Galderma Laboratories, L.P.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error